AML treatment ICT01 granted FDA’s orphan drug status
ICT01, an immune-modulating therapy being developed by Imcheck Therapeutics for acute myeloid leukemia (AML), has been granted orphan drug status by the U.S. Food…
ICT01, an immune-modulating therapy being developed by Imcheck Therapeutics for acute myeloid leukemia (AML), has been granted orphan drug status by the U.S. Food…
Quemliclustat has been granted an orphan drug designation in the U.S. as a potential treatment for pancreatic cancer. The U.S. Food and Drug Administration…
July 16 marks Glioblastoma Awareness Day (GBM Day), an annual observance dedicated to raising awareness about the rare and aggressive form of brain cancer, promoting…
Senti Biosciences‘ experimental cell therapy SENTI-202 has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) as a potential therapy…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GLIX1, a cancer treatment now in the preclinical stages of development, as…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ADoBind MC001, an experimental treatment for pancreatic cancer that’s being developed…
A European Medicines Agency (EMA) committee recommended that Darzalex (daratumumab) given as an under-the-skin injection be approved for people with smoldering multiple myeloma (SMM)…
Most people with advanced pancreatic cancer who received first-line treatment with atebimetinib were alive and free from disease progression six months after starting treatment,…
Most people with hard-to-treat multiple myeloma who were given a combination treatment of Talvey (talquetamab-tgvs) and Tecvayli (teclistamab-cqyv) in a clinical trial were alive…
Nearly 1 in 4 people with NPM1-mutated acute myeloid leukemia (AML) achieved complete remission after treatment with ziftomenib in a Phase 2 clinical trial. Dubbed…